**Name of Journal:** *World Journal of Clinical Cases*

**Manuscript NO:** 62978

**Manuscript Type:** CASE REPORT

**Thymosin as a possible therapeutic drug for COVID-19: A case report**

Zheng QN *et al*. Thymosin as a drug for COVID-19

Qiong Na Zheng, Mei Yan Xu, Fang Min Gan, Sha Sha Ye, Hui Zhao

**Qiong Na Zheng, Mei Yan Xu, Fang Min Gan, Sha Sha Ye, Hui Zhao,** Department of Infectious Diseases, The Affiliated Yueqing Hospital, Wenzhou Medical University, Yueqing 325600, Zhejiang Province, China

**Author contributions:** Zheng QN and Zhao H reviewed the literature and drafted the manuscript; Ye SS drafted all figures; Zheng QN, Xu MY, and Gan FM treated the patient and participated in collecting the data; Zhao H guided the treatment; all authors read and approved the final manuscript.

**Supported by** the Project for Science and Technology of Wenzhou, No. Y2020278.

**Corresponding author: Hui Zhao, MD, Chief Doctor,** Department of Infectious Diseases, The Affiliated Yueqing Hospital, Wenzhou Medical University, No. 338 Qingyuan Street, Yueqing 325600, Zhejiang Province, China. 304764851@qq.com

**Received:** January 22, 2021

**Revised:** March 28, 2021

**Accepted:** April 6, 2021

**Published online:**

**Abstract**

BACKGROUND

There are no effective antiviral therapies for coronavirus disease 2019 (COVID-19) at present. Although most patients with COVID-19 have a mild or moderate course of disease, up to 5%-10% of patients may have a serious and potentially life-threatening condition, indicating an urgent need for effective therapeutic drugs. The therapeutic effect of thymosin on COVID-19 has not been previously studied. In this paper, for the first time we report a case of thymosin treatment of COVID-19.

CASE SUMMARY

A 51-year-old man with imported COVID-19 was admitted with definite symptoms of chest tightness, chest pain, and fatigue. The polymerase chain reaction results for severe acute respiratory syndrome coronavirus 2 were negative. The antibody test was positive, confirming the diagnosis of COVID-19. As many orally administered drugs were not well tolerated due to gastrointestinal symptoms, an emergency use of thymosin, a polypeptide consisting of 28 amino acids, was administered by injection. Finally, after the implementation of the treatment program, symptoms and lung imaging improved significantly.

CONCLUSION

In this case report, it is confirmed that thymosin may help alleviate the severity of COVID-19 symptoms.

**Key Words:** COVID-19; Thymosin; SARS-CoV-2; Treatment; Therapeutic drug; Case report

Zheng QN, Xu MY, Gan FM, Ye SS, Zhao H. Thymosin as a possible therapeutic drug for COVID-19: A case report. *World J Clin Cases* 2021; In press

**Core Tip:** A 51-year-old Chinese man returned from Russia to Yueqing Hospital Affiliated to Wenzhou Medical University on April 27, 2020. He had 2-wk symptoms of chest pain, chest tightness, fatigue, and conscious fever. Oxygen inhalation was given and thymosin was injected twice a week, at 1.6 mg per injection. The patient was successfully treated and discharged after 15 d in the hospital.

**INTRODUCTION**

Since the outbreak in China in December 2019, coronavirus disease 2019 (COVID-19) has spread worldwide[1]. The numbers of infections and deaths have increased significantly[2]. Although there are many reports on the treatment of COVID-19, it is clear that currently no specific drugs are available to treat COVID-19 infection[3]. Thus, new treatment strategies for COVID-19 are urgently needed to be developed. Research confirms that COVID-19 is a human-to-human transmission caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)[4]. Similar to other virally infectious diseases, the immune function plays a decisive role in the consequences of viral infection. The prognosis of the elderly and immunocompromised patients is therefore often poor[5]. Thymosin, a polypeptide consisting of 28 amino acids, can effectively regulate the body’s immunity by inducing the differentiation and maturation of T cells and enhancing the production of cytokines and B cell antibody responses, resulting in enhanced immunity in patients[6]. At the time of this writing, no thymosin-like treatment of COVID-19 has been reported. Herein, we report a clinical case of COVID-19, and introduce the effect of thymosin on the symptoms, imaging, and prognosis of a COVID-19 patient. It is hoped that this report can enrich our understanding of the current treatments for COVID-19 and explore the therapeutic potential of thymosin for patients with COVID-19.

**CASE PRESENTATION**

***Chief complaints***

A 51-year-old male patient had 2-wk symptoms of chest pain, chest tightness, fatigue, and conscious fever.

***History of present illness***

On April 13, 2020, the patient developed chest pain, chest tightness, fatigue, and conscious fever, and was not treated in Russia. On April 27, 2020, he was admitted to Yueqing Hospital Affiliated to Wenzhou Medical University for treatment.

***History of past illness***

The patient had no history of hypertension, diabetes, or other systemic diseases.

***Personal and family history***

The patient had no history of smoking or underlying lung disease or any other risk factors. His family members were healthy.

***Physical examination***

Physical examination showed that a body temperature of 37.9 °C, blood pressure of 132/87 mmHg, pulse of 94 beats per minute, respiration of 20 breaths per minute, and SPO2 of 94%. Moist rales were heard in the right lung.

***Laboratory examinations***

The results showed a white blood cell count of 4.6 × 109 cells/L (reference range: 4.0-10.0 × 109 cells/L). Reverse transcription polymerase chain reaction (RT-PCR) for SARS-CoV-2 was negative. The IgM antibodies for common pathogens such as influenza A, influenza B, adenovirus, respiratory syncytial virus, parainfluenza, Mycoplasma pneumoniae, and Chlamydia pneumoniae were all negative. SARS-CoV-2-specific IgM and IgG antibodies (the results of the kit produced by Xiamen Innodx Biotech Co., Ltd., China) were immediately detected and the results were all positive.

***Imaging examinations***

On April 28, chest computed tomography (CT) showed multiple patchy shadows and ground glass shadows in both lungs (Figure 1A). On May 1, chest CT showed obvious absorption of both lungs lesions (Figure 1B). On May 11, reexamination of chest CT showed that the lesions in both lungs were absorbed (Figure 1C)

**FINAL DIAGNOSIS**

The final diagnosis was COVID-19.

**TREATMENT**

The patient was then sent to the air isolation ward for clinical observation and immediately given an oxygen therapy. The patient was also treated with arbidol and lopinavir-ritonavir, but due to obvious nausea, vomiting, and diarrhea, the drug treatments were halted. On April 28, thymosin was subcutaneously injected twice a week, at 1.6 mg per injection.

**OUTCOME AND FOLLOW-UP**

At the follow-up one month after discharge, the patient showed no discomfort, and the chest CT lesions were completely absorbed.

**DISCUSSION**

In this case, although the RT-PCR results were negative for SARS-CoV-2, the specific IgM and IgG antibodies for SARS-CoV-2 were all positive, indicating a clear diagnosis of COVID-19[7]. The patient was initially treated with arbidol and lopinavir-ritonavir, but because of severe nausea, vomiting, and diarrhea, the treatment was switched to thymosin injection, which was the only medicine. To date, the pathogenesis of COVID-19 is not clearly understood and there are no effective drug treatments available for the disease. Although various therapeutic drugs have been reported, their biological effects are non-specific. Thymosin, as an immune enhancer, has a therapeutic potential for the treatment of infections and immunocompromised diseases such as cancer[6,8,9]. Thymosin is a hormone with 28 amino acids naturally secreted by the thymus. It has a variety of immunomodulatory activities. It can activate Toll-like receptors in dendritic cells and other immune cells, thus enhancing the function of T-helper 1 cells, natural killer cell activity, and antibody response to T-cell-dependent antigen[10,11]. Thymosin has been used in China for the treatment of viral hepatitis for more than two decades[12]. The reason may be that thymosin can promote T lymphocyte responses and function involved in the host antiviral defenses. We report here an effective case of thymosin injection for the treatment of COVID-19 when other available antiviral drugs could not be tolerated. However, further studies are still needed to explain the exact efficacy and mechanism of thymosin on COVID-19. We summarize the patient's course of therapy schedule (Figure 2). The symptoms of chest tightness, chest pain, and fatigue gradually improved under the action of thymosin alone. Thymosin therapy may also increase the survival rate of sepsis and reduce the bacterial load in a sepsis model as reported by King and Tuthill[13]. Although there are no large-scale studies, considering the encouraging result and the proven safety for human use, we believe that thymosin may be a feasible therapeutic drug against COVID-19 and warrants further investigation. Clinical trials can verify the role of thymosin in alleviating the symptoms of COVID-19 and shortening the course of treatment in a large cohort.

**CONCLUSION**

Relieving symptoms, safeness, and effectiveness make thymosin a potentially ideal choice for the treatment of COVID-19. Although we had only one case, as described here, the significant effect in alleviating symptoms of COVID-19 demonstrates the potential therapeutic effect of this naturally derived compound.

**REFERENCES**

1 **Zu ZY**, Jiang MD, Xu PP, Chen W, Ni QQ, Lu GM, Zhang LJ. Coronavirus Disease 2019 (COVID-19): A Perspective from China. *Radiology* 2020; **296**: E15-E25 [PMID: 32083985 DOI: 10.1148/radiol.2020200490]

2 **Dong E**, Du H, Gardner L. An interactive web-based dashboard to track COVID-19 in real time. *Lancet Infect Dis* 2020; **20**: 533-534 [PMID: 32087114 DOI: 10.1016/S1473-3099(20)30120-1]

3 **Sanders JM**, Monogue ML, Jodlowski TZ, Cutrell JB. Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review. *JAMA* 2020; **323**: 1824-1836 [PMID: 32282022 DOI: 10.1001/jama.2020.6019]

4 **Phan T**. Genetic diversity and evolution of SARS-CoV-2. *Infect Genet Evol* 2020; **81**: 104260 [PMID: 32092483 DOI: 10.1016/j.meegid.2020.104260]

5 **Márquez EJ**, Trowbridge J, Kuchel GA, Banchereau J, Ucar D. The lethal sex gap: COVID-19. *Immun Ageing* 2020; **17**: 13 [PMID: 32457811 DOI: 10.1186/s12979-020-00183-z]

6 **Ciancio A**, Rizzetto M. Thymalfasin in the treatment of hepatitis B and C. *Ann N Y Acad Sci* 2010; **1194**: 141-146 [PMID: 20536462 DOI: 10.1111/j.1749-6632.2010.05487.x]

7 **National Health Commission of the People’s Republic of China.** Diagnosis and treatment protocol for COVID-19 (Trial Version 7). [cited 20 March 2020]. Available from: http://en.nhc.gov.cn/2020-03/29/c\_78469.htm

8 **Xue XC**, Yan Z, Li WN, Li M, Qin X, Zhang C, Hao Q, Wang ZL, Zhao N, Zhang W, Zhang YQ. Construction, expression, and characterization of thymosin alpha 1 tandem repeats in Escherichia coli. *Biomed Res Int* 2013; **2013**: 720285 [PMID: 23555093 DOI: 10.1155/2013/720285]

9 **Morton B**, Pennington SH, Gordon SB. Immunomodulatory adjuvant therapy in severe community-acquired pneumonia. *Expert Rev Respir Med* 2014; **8**: 587-596 [PMID: 24898699 DOI: 10.1586/17476348.2014.927736]

10 **Romani L**, Bistoni F, Gaziano R, Bozza S, Montagnoli C, Perruccio K, Pitzurra L, Bellocchio S, Velardi A, Rasi G, Di Francesco P, Garaci E. Thymosin alpha 1 activates dendritic cells for antifungal Th1 resistance through toll-like receptor signaling. *Blood* 2004; **103**: 4232-4239 [PMID: 14982877 DOI: 10.1182/blood-2003-11-4036]

11 **Romani L**, Bistoni F, Perruccio K, Montagnoli C, Gaziano R, Bozza S, Bonifazi P, Bistoni G, Rasi G, Velardi A, Fallarino F, Garaci E, Puccetti P. Thymosin alpha1 activates dendritic cell tryptophan catabolism and establishes a regulatory environment for balance of inflammation and tolerance. *Blood* 2006; **108**: 2265-2274 [PMID: 16741252 DOI: 10.1182/blood-2006-02-004762]

12 **Gramenzi A**, Cursaro C, Andreone P, Bernardi M. Thymalfasin: clinical pharmacology and antiviral applications. *BioDrugs* 1998; **9**: 477-486 [PMID: 18020580 DOI: 10.2165/00063030-199809060-00005]

13 **King RS**, Tuthill C. Evaluation of thymosin α 1 in nonclinical models of the immune-suppressing indications melanoma and sepsis. *Expert Opin Biol Ther* 2015; **15** Suppl 1: S41-S49 [PMID: 25643200 DOI: 10.1517/14712598.2015.1008446]

**Footnotes**

**Informed consent statement:** The patient provided written informed consent for his medical information to be stored and used in the hospital database at the first visit to our center.

**Conflict-of-interest statement:** The authors declare that they have no competing interests to report.

**CARE Checklist (2016) statement:** The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/

**Manuscript source:** Unsolicited manuscript

**Peer-review started:** January 22, 2021

**First decision:** March 25, 2021

**Article in press:**

**Specialty type:** Infectious diseases

**Country/Territory of origin:** China

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): B


Grade C (Good): C

Grade D (Fair): 0


Grade E (Poor): 0

**P-Reviewer:** Aktas S, Shayestehpour M **S-Editor:** Zhang H **L-Editor:** Wang TQ **P-Editor:**

**Figure Legends**



**Figure 1 Chest computed tomography results of the coronavirus disease 2019 patient.** A: Computed tomography (CT) of the chest on April 28. Blue arrows show multiple patchy shadows and ground glass shadows in both lungs; B: CT of the chest on May 1. Red arrows show obvious absorption of the lesions in both lungs; C: CT of the chest on May 11. Green arrows show that the lesions in both lungs were absorbed.



**Figure 2 Symptoms and treatments of the patient outlined accordingly to days post symptom onset since April 27, 2020.**